A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia
a study on Beta Thalassemia
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 subjects ≤50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0/β0, β0/IVS-I-110, or IVS-I-110/IVS-I-110 genotype. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.
A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age
Beta-Thalassemia Thalassemia LentiGlobin BB305 Drug Product
You can join if…
Open to people ages up to 50 years
- Subjects ≤50 years of age at the time of consent or assent (as applicable), and able to provide written consent (adults, or legal guardians, as applicable) or assent (adolescents or children). Provided that the DMC has approved enrolling subjects younger than 5 years of age, subjects younger than 5 years of age may be enrolled if they weigh a minimum of 6 kg and are reasonably anticipated to be able to provide at least the minimum number of cells required to initiate the manufacturing process.
- Diagnosis of TDT with a history of at least 100 mL/kg/year of packed red blood cells (pRBCs) in the 2 years preceding enrollment (all subjects), or be managed under standard thalassemia guidelines with ≥8 transfusions of pRBCs per year in the 2 years preceding enrollment (subjects ≥12 years).
- Clinically stable and eligible to undergo HSCT.
- Treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.
You CAN'T join if...
- Presence of a mutation characterized as other then β0 (e.g., β+, βE, βC) on at least one HBB allele.
- Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV).
A white blood cell (WBC) count <3×109/L, and/or platelet count <100×109/L not related to hypersplenism.
- Uncorrected bleeding disorder.
- Any prior or current malignancy.
- Prior HSCT.
- Advanced liver disease.
- A cardiac T2* <10 ms by magnetic resonance imaging (MRI).
- Any other evidence of severe iron overload that, in the investigator's opinion, warrants exclusion.
- Participation in another clinical study with an investigational drug within 30 days of Screening.
- Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or investigator.
- Prior receipt of gene therapy.
- Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile subjects.
- A known and available HLA-matched family donor.
- Any contraindications to the use of G-CSF and plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients.
- UCSF Benioff Children's Hospital Oakland
accepting new patients
Oakland California 94609 United States
- Ann & Robert H. Lurie Children's Hospital of Chicago
accepting new patients
Chicago Illinois 60611 United States
- accepting new patients
- Start Date
- Completion Date
- bluebird bio
- Phase 3
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03207009.